BioStem Technologies (BSEM) to Release Quarterly Earnings on Thursday

Key Points

• BioStem Technologies is scheduled to announce its Q2 2025 earnings on August 11th, with expectations of earning $0.32 per share and revenue of $78.22 million.
• In its previous earnings report, BioStem missed estimates significantly, posting only $0.17 earnings per share against an expected $1.25.
• The company's stock is currently trading at $11.42, with a market capitalization of $191.22 million and a PE ratio of 7.77.

BioStem Technologies (OTCMKTS:BSEM - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Thursday, August 14th. Analysts expect BioStem Technologies to post earnings of $0.32 per share and revenue of $78.22 million for the quarter.

BioStem Technologies (OTCMKTS:BSEM - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $1.25 by ($1.08). The company had revenue of $72.53 million during the quarter, compared to analyst estimates of $101.20 million. On average, analysts expect BioStem Technologies to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

BioStem Technologies Stock Down 0.2%

OTCMKTS BSEM traded down $0.02 on Friday, reaching $10.35. The company had a trading volume of 49,797 shares, compared to its average volume of 48,389. The stock's 50 day moving average is $12.27 and its 200-day moving average is $12.42. The stock has a market cap of $173.36 million, a price-to-earnings ratio of 7.04 and a beta of -0.29. BioStem Technologies has a 52 week low of $6.95 and a 52 week high of $28.26.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.